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OBJECTIVE — Early use of insulin after diagnosis of type 2 diabetes is met with resistance
because of associated weight gain, hypoglycemia, and fear of decreased compliance and quality
of life (QoL).
RESEARCH DESIGN AND METHODS — In treatment-naive patients with newly di-
agnosedtype2diabetes,insulinandmetforminwereinitiatedfora3-monthlead-inperiod,then
patients were randomly assigned to insulin and metformin (insulin group) or metformin, pio-
glitazone, and glyburide (oral group) for 36 months. Hypoglycemic events, compliance, A1C,
weight, QoL, and treatment satisfaction were assessed.
RESULTS — Of 29 patients randomly assigned into each group, 83% (insulin group) and
72% (oral group) completed this 3-year study. At study completion, A1C was 6.1  0.6%
(insulin group) versus 6.0  0.8% (oral group). Weight increased similarly in both groups (P 
0.09) by 4.47 kg (95% CI 0.89–8.04 kg) (insulin group) and 7.15 kg (95% CI 4.18–10.13 kg)
(orals group). Hypoglycemic events did not differ between groups (mild 0.51 event/person-
monthintheinsulingroupvs.0.68event/person-monthintheoralsgroup,P0.18andsevere
0.04 event/person-year in the insulin group vs. 0.09 event/person-year in the orals group, P 
0.53). Compliance, QoL, and treatment satisfaction were similar between groups, with 100% of
patients randomly assigned to insulin willing to continue such treatment.
CONCLUSIONS — When compared with a clinically equivalent treatment regimen, insu-
lin-basedtherapyiseffectiveanddidnotcausegreaterweightgainorhypoglycemianordecrease
compliance, treatment satisfaction, or QoL. Insulin is safe, well-accepted, and effective for
ongoing treatment of patients with newly diagnosed type 2 diabetes.
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ype 2 diabetes is characterized by a
progressive loss of -cell function
that results in deterioration of glu-
cose control, which increases the inci-
dence of diabetes-related complications.
There are substantial data associating
chronic hyperglycemia with long-term
micro- and macrovascular complications
(1–4), supporting the need for stringent
glycemic control. Chronic hyperglycemia
is thought to contribute to pancreatic
-cell dysfunction and loss of insulin se-
cretory capacity by exerting a glucotoxic
effect (5) and possibly exhaustion from
the increased demand (6). This self-
perpetuating cycle leads to progressive
and often profound insulin deﬁciency,
andsuchpatientsultimatelyrequireinsu-
lin to maintain their A1C level at goal. In
the UK Prospective Diabetes Study, only
9% of patients randomized to therapy
withdietalonehadA1Clevelof7.0%at
9yearsfollow-up(7).Inthatsamecohort,
53% of patients receiving sulfonylurea
therapy required insulin therapy within 6
years (8).
Insulin is the most effective hypogly-
cemic agent in our treatment armamen-
tarium and is now recommended by the
American Diabetes Association (ADA)
guidelines (9) as the second agent added
aftermetformin.Insulinisalsothoughtto
protect -cell function decline (10),
therefore exerting a “disease-modifying”
effect.Yetthereisresistancetoinsulinini-
tiation among physicians and patients
alike, not only as an early treatment op-
tion but also when oral hypoglycemic
agents fail to control glucose levels (11).
Some commonly cited barriers to insulin
initiation are patient fear of disease pro-
gressionandneedleanxiety,aswellaspa-
tientandproviderfearsofweightgainand
hypoglycemic episodes (12). For these
reasons, insulin has traditionally been
viewedasalastresortforpatientswhofail
to maintain glycemic control with diet
and oral hypoglycemic drugs.
However, previous studies have
shown comparable weight gain, edema,
and lipid changes in a comparison of in-
sulin glargine or rosiglitazone added to a
combination of sulfonylurea and met-
formintherapy.Insulintherapywasmore
cost-effective and produced greater re-
ductions in A1C, when the baseline A1C
was 9.5% (13). When an insulin and
metformin treatment regimen was com-
pared with addition of a third oral hypo-
glycemic agent after failure of two oral
agents, patients with triple oral therapy
were less likely to complete the regimen
due to lack of efﬁcacy or intolerable side
effects (14). Studies suggest that short-
term treatment with insulin after diagno-
sis (15) or at time of “secondary drug
failure”(16)improves-cellfunctionand
metabolic control. To evaluate the feasi-
bility of an insulin-based regimen as ﬁrst-
line treatment for type 2 diabetes we
compared compliance, satisfaction, qual-
ity of life (QoL), effectiveness, and safety
in patients with newly diagnosed type 2
diabetes randomly assigned to triple oral
hypoglycemic therapy or an insulin-
based regimen.
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METHODS— Patients between the
ages of 21 and 70 years, with the diagno-
sisoftype2diabeteswithintheprevious2
months and who were treatment naive
were recruited from Parkland Memorial
Hospitalinpatientandoutpatientservices
or by self-referral to the Clinical Diabetes
Research Clinic at University of Texas
Southwestern. Patients with type 1 diabe-
tes–related antibodies, a baseline A1C
level 7%, an elevated serum creatinine
level, a clinical history of heart failure, a
history of lactic acidosis, untreated prolif-
erative diabetic retinopathy, any life-
threatening conditions, or use of more
than two alcoholic drinks/day or illicit
drug use within the 6 months before en-
rollment were excluded. Women who
werepregnantordesiredtobecomepreg-
nant were not enrolled. The study was
approved by the institutional review
board of the University of Texas South-
western, and written informed consent
was obtained from all subjects preceding
the start of the study.
This was an open-label randomized
trialcomparingtripleoraltherapywithan
insulinplusmetforminregimen.Afteren-
rollment,insulinandmetforminwereini-
tiated in all patients for a 3-month lead-in
treatment period. This lead-in period had
a dual purpose: 1) to homogenize the gly-
cemic control of the study population at
the time of randomization; and 2)t oe x -
poseallsubjectstoaninsulin-basedtreat-
ment regimen that would serve as a real-
life comparison for treatment satisfaction
and lifestyle impact assessment after
randomization.
Diabetes education and nutritional
counseling were provided to all patients
at enrollment in the study and reinforced
at the time of randomization. Upon en-
rollment, treatment was started with 0.2
unit   kg
1   24 h
1 of Insulin NovoLog
Mix70/30withFlexPendelivery,divided
into two equal doses to be injected imme-
diately before breakfast and supper. Met-
formin was started at a dose of 500 mg/
day and increased weekly by increments
of 500 mg/day to a goal dose of 1,000 mg
twice daily. Results of this study period
were published previously (17).
After 3 months of treatment, patients
were randomly assigned to either con-
tinue insulin and metformin or begin tri-
ple oral therapy. Treatment assignment
was determined with a stratiﬁed, block
randomization scheme programmed by
the biostatistician (B.A.H.) using SAS
Proc Plan software. The randomization
was stratiﬁed by race (African American
or non–African American) and BMI (35
kg/m
2 or 35 kg/m
2), generating four
blocked,randomizedlistsoftreatmentas-
signments, one for each stratum. The
principal investigator assigned treatment
sequentially from these randomized lists
as the participant reached the randomiza-
tion visit.
Patients randomly assigned to triple
oral therapy continued metformin and
started 1.25 mg glyburide twice daily and
15 mg daily pioglitazone. Pioglitazone
was titrated monthly to a ﬁnal dose of 45
mg daily. Titration of insulin and gly-
buride (up to the highest clinically effec-
tive dose of 10 mg daily) was performed
by the study physician throughout the
study, based on home blood glucose
monitoring logs targeting a fasting blood
glucose level of 70–110 mg/dl and post-
prandial blood glucose level of 140 mg/
dl. All patients were asked to monitor
blood glucose at least twice daily, regard-
less of the group assignment. Initiation
and dose adjustment of antihypertensive
and lipid-lowering agents were allowed if
medically necessary. Patients were fol-
lowed at the Clinical Diabetes Research
Clinic at University of Texas Southwest-
ern monthly for the ﬁrst 4 months, at
6 months after randomization, and every
3 months thereafter for a total of 36
months.“Treatmentfailure,”apredeﬁned
study end point, was deﬁned as A1C
8%andconﬁrmedbyasecondreading,
occurring after maximization of the gly-
buride dose or adequate insulin dose ad-
justments. Volunteers randomly assigned
to the triple oral group who reached this
endpointweretransitionedtoinsulinand
metformin treatment, whereas those ran-
domly assigned to insulin continued with
thesametreatment.Follow-upaftertreat-
ment failure continued as scheduled.
Measurements
A1C was performed at each visit, using
high-performance liquid chromatogra-
phy in the Clinical Diabetes Laboratory at
University of Texas Southwestern. Rou-
tine chemistry studies, hematology, and a
lipid panel were performed by a commer-
ciallaboratory(QuestDiagnostics,Irving,
TX).
Weight, blood pressure, hypoglyce-
micevents,andcompliancewereassessed
at every visit. Mild hypoglycemic epi-
sodes were deﬁned as symptoms indica-
tiveoflowbloodglucoseaccompaniedby
a documented capillary blood glucose
valueof70mg/dl.Severehypoglycemia
was deﬁned as symptoms of hypoglyce-
mia that required assistance from another
individual for treatment, regardless of
capillary blood glucose level. Patients
were instructed to return their unused
medications at every visit for inventory
andestimationofpatientcompliance.We
reported the average compliance of all
study medications in each group.
QoL was measured at randomization
and also 6 and 18 months later using the
modiﬁed Diabetes Quality of Life Clinical
Trial Questionnaire (supplementary
material available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc09-0653/DC1). This ques-
tionnaire addresses several areas with
respect to diabetes QoL: satisfaction with
treatment, impact of treatment, worry
aboutfutureeffectsofdiabetes,andworry
about social issues (18), in addition to a
hypoglycemia worry scale, a lifestyle ﬂex-
ibility scale, and ﬁve separate questions
concerning the patient’s treatment satis-
faction with insulin and perception of
their own health (19). Answers are in the
form of a Likert scale score of 1–5, with a
lower score demonstrating greater im-
pact, worry, or satisfaction. For patients
randomly assigned to triple oral therapy,
questions regarding treatment satisfac-
tion with insulin were omitted. For each
subscale, the mean of individual item
scores was reported. This questionnaire
was chosen because it addresses illness-
speciﬁcissues,aswellasinsulintreatment
issues (20) to best identify excess disease
burden due to insulin treatment.
Statistical analysis
For continuous variables, we computed
means  SD and 95% CI. For categorical
variables, we computed percentages. To
compare weight gain and A1C control in
thepresenceofmissingdataduetolossof
follow-up or treatment failure, we
adopted two strategies. The ﬁrst strategy
was to estimate the slope of the treatment
effects using a linear mixed model, with
random effects accounting for the corre-
lation among multiple observations from
each subject. Then we compared treat-
ment effects based on slope estimation.
For this strategy we used all available ob-
servations.Thesecondstrategywastouse
a t test based on complete data from
subjects who ﬁnished the study (“com-
pleters” analysis). Mild and severe hypo-
glycemic event rates were compared
among groups with Poisson regression
models using a general estimating equa-
tions approach to incorporate the re-
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QoLquestionnaireat0,6,and18months
were compared between and within
groups as repeated measures using mixed
models. Statistical signiﬁcance was de-
clared at 5%.
As speciﬁed a priori in the protocol,
data collected after treatment failure were
not included in the per-protocol analysis
described above. To conﬁrm our results,
we also performed an intention-to-treat
analysis, in which all data were analyzed
as randomized. All results presented be-
low are consistent with those obtained
under the intention-to-treat analysis.
RESULTS— Fifty-eight patients were
randomly assigned at the end of the
3-month run-in period: 29 continued in-
sulin-basedtreatmentand29begantriple
oral therapy. The baseline characteristics
ofthesetwogroupsaredescribedinTable
1.VolunteerswererecruitedbetweenNo-
vember 2003 and June 2005 with fol-
low-up through September 2008. The
completion rate of this 3-year study was
83% (24 of 29) in the insulin-treated
group and 72% (21 of 29) in the triple
oral group (supplementary ﬁgure, avail-
able in an online appendix). Reasons for
dropout were as follows: insulin group,
fourvolunteerswerelosttofollow-upand
one volunteer moved out of town; oral
hypoglycemic group, four volunteers
were lost to follow-up, three volunteers
moved out of town, and one volunteer
became pregnant (delivered a healthy
infant).
Glycemic control
A1C improved from 10.8 to 5.9% during
the 3-month lead-in period (17). This ex-
cellent degree of glycemic control was
maintained throughout the 3-year study
follow-up (Fig. 1A). Based on per-
protocol analysis of the participants who
ﬁnished the study, at completion, A1C in
the insulin-treated group was 6.1  0.6
versus6.00.8%inthetripleoralgroup
(P  0.26). The linear mixed model did
not show a signiﬁcant difference in treat-
ment effects between the two groups ei-
ther (P  0.41). The percentage of
patients meeting the ADA guideline treat-
ment target of A1C 7.0% was 100% in
bothgroupsatbaseline;92%(22of24)of
patientsintheinsulingroupand76%(16
of 21) of patients in the triple oral group
met that guideline at the end of 36
months. The average insulin dose at the
time of randomization was 64  31 units
(0.63  0.29 units/kg); at the end of the
follow-up, the insulin dose in the insulin-
treated group increased to 80  61 units
(0.75  0.40 units/kg).
Three patients in each group
reached the “treatment failure” end
point. These failures occurred earlier in
the triple oral group (at 9, 10, and 12
monthsafterrandomization)thaninthe
insulin group (at 18, 21, and 27 months
after randomization).
Safety
The overall number of hypoglycemic
events was low throughout the study, de-
spite the use of a conservative deﬁnition
for hypoglycemia. The insulin group had
0.51 mild hypoglycemia events/person-
month and the triple oral group had 0.68
event/person-month (P  0.18). The in-
sulin group averaged 0.04 severe hypo-
glycemic event/person-year, and the
triple oral group averaged 0.09 event/
person-year (P  0.53). Overall, 55 of 58
participants had at least one episode of
hypoglycemia.
More than 76% of our study popula-
tion was obese at randomization. “Com-
Table 1—Baseline characteristics of the study population at randomization
Insulin-treated
group
Triple oral
group
Age (years) 44.75  9.7 45.00  10.7
Sex (male/female) 20/9 17/12
Ethnicity
African American 12 (41) 13 (45)
White 6 (20) 4 (14)
Hispanic 11 (38) 11 (38)
Other 0 (0) 1 (3)
Weight (kg) 102  25 101  23
BMI (kg/m
2) 35.6  6.6 36.5  7.0
Systolic blood pressure (mmHg) 125  15.8 123  13.6
Diastolic blood pressure (mmHg) 76  10.4 78  9.7
A1C (%) 6.0  0.5 5.9  0.5
Fasting glucose (mg/dl) 112  24.7 102  19.1
Fasting insulin (U/ml) 25  35.9 23  22.0
Total cholesterol (mg/dl) 170  38.5 171  32.4
LDL cholesterol (mg/dl) 97  33.7 102  29.8
HDL cholesterol (mg/dl) 41  9.6 42  10.8
Triglycerides (mg/dl) 172  159.3 136  73.0
Data are means  SD or n (%).
Figure 1—A1C (A), weight (B), and compli-
ance (C) of the insulin treatment group (f)
and the triple oral group (E) during the 36-
month study. The results are reported as
means  SD.
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triple oral group had a signiﬁcantly
greater weight gain than the insulin
group: 10.10 kg (95% CI 4.46–15.74)
versus 3.36 kg (0.47 to 7.20) (P 
0.04). The linear mixed model, however,
did not detect a signiﬁcant difference in
weight gain between two groups. The es-
timated weight gain at study completion
was4.47kg(0.89–8.04kg)intheinsulin
groupand7.15kg(4.18–10.13kg)inthe
triple oral group (P  0.09). Neither re-
sult supports the claim that insulin ther-
apy leads to a greater weight gain. Both
groups gained weight, but although the
weight gain persisted over time in the
group treated with oral hypoglycemic
agents, the weight gain in the insulin-
treated group leveled off after 18 months
and even regressed toward the baseline
(Fig. 1B).
Two patients experienced serious ad-
verse reactions to pioglitazone (diuretic-
resistant severe pedal edema and heart
failure), which required discontinuation
of the medication. The most common
treatment-relatedsideeffectsweregastro-
intestinal in nature, occurred equally in
both groups, and were related to use of
metformin (5% of patients). None were
severe enough to require study drug
discontinuation.
Compliance, satisfaction, and
quality of life
Compliance with study medications was
high throughout the trial: 93% in the in-
sulin-treated group and 90% in the triple
oral group (Fig. 1C). There were no be-
tween-group differences for any of the 12
QoL domains evaluated (Fig. 2). Both
groups showed improvement over time
with respect to social worries, but all
other domains remained constant
through follow-up. All patients randomly
assigned to receive insulin reported satis-
faction with insulin treatment and will-
ingness to continue insulin at 18 months
after randomization.
Metabolic comorbidities
Results of the systolic and diastolic blood
pressure and lipid proﬁle components at
the time of randomization are presented
in Table 1. After 30 months, total choles-
terol, LDL, HDL, and triglyceride levels
averaged 164  43.7, 90  39.9, 45 
13.5,and13959.8mg/dl,respectively,
in the insulin group and 172  30.4,
98  28.6, 48  13.1, and 135  75.7
mg/dl, respectively, in the triple oral
group. At the end of the study, 91% of
patients in the insulin group required at
least one cholesterol-lowering medica-
tion, compared with 67% of patients in
the triple oral group.
Systolic and diastolic blood pressures
at the end of the study averaged 126 
13.9 and 79  6.9 mmHg, respectively,
in the insulin group and 136  17.0 and
80.8  13.1 mmHg, respectively, in the
triple oral group. At the end of the study,
72% of patients in the insulin group re-
quired at least one antihypertensive med-
ication,comparedwith83%ofpatientsin
the oral group.
CONCLUSIONS— Diabetes is char-
acterized by a progressive loss of -cell
function and glycemic control. Poor gly-
cemic control leads to macro- and micro-
vascular complications, identifying a
need for effective, simple treatment regi-
mens with high levels of patient compli-
ance.Ithasbeenshownpreviouslythatan
insulin plus metformin regimen is effec-
tiveandsafeasashort-termtreatmentop-
tion to gain rapid glycemic control (17).
Our data show that long-term continua-
tion of this regimen is equally effective,
safe, and well accepted by patients com-
pared with a combination of three oral
hypoglycemic agents.
The progressive nature of type 2 dia-
betes makes the durability of a treatment
regimen of utmost importance in consid-
eration of treatment options. The tradi-
tional approach to diabetes treatment
calls for addition of subsequent oral
agents when A1C is 8%, with insulin
being considered the last resort (11). This
“treat-to-failure” approach leads to long
periods of hyperglycemia preceding any
treatment intensiﬁcation, which contrib-
ute to microvascular complications and
-cell glucotoxicity that in turn acceler-
atestreatmentfailure.Insulintreatmentis
thought to have a beneﬁcial effect on
-cell function through rest of the -cell
as well as prevention of the toxic effect of
hyperglycemia on the -cell. We de-
signedourstudytocomparetheearlyand
long-term changes in -cell function in
patients with newly diagnosed type 2 di-
abetestreatedwithinsulinandmetformin
versus an intensive, commonly used, oral
hypoglycemic treatment regimen consist-
ingofmetformin,glyburide,andpioglita-
zone. The most recent ADA consensus
statement (9) encourages early use of in-
sulin, whereas commonly used agents
such as thiazolidinediones are considered
second tier. These guidelines were met
with criticism, mostly on the basis that
insulintreatmentisassociatedwithhypo-
glycemia, weight gain, and low treatment
satisfaction and compliance. In light of
thisdebate,wereporttherateofhypogly-
cemia, weight gain, treatment satisfac-
tion,compliance,andQoLover3yearsof
follow-up in this ongoing randomized
clinical trial.
Patients in our study had an average
A1C 10% at enrollment and achieved
an A1C reduction of 5% in the 3-month
lead-in phase of the study using insulin
and metformin. This excellent glycemic
control was maintained throughout the
3-yearfollow-upinbothgroups,showing
that both treatment regimens are effective
and durable in patients with newly diag-
nosed type 2 diabetes. We were surprised
to ﬁnd that after 36 months of treatment
there was no difference in A1C between
the insulin and triple oral group, as even
with pharmacologic treatment there is
known progressive deterioration in blood
glucose control during the ﬁrst few years
ofdiagnosis(7,21).Mostpreviousstudies
used monotherapy or a two-drug combi-
nation; thus, three drugs may be more ef-
fective than one or two. However, we
suspect that the efﬁcacy and durability of
triple oral therapy in our study is related
to the initial insulin treatment with sub-
sequent reduction in glucotoxicity.
Hypoglycemia and weight gain are
the most common treatment-related side
effects associated with insulin treatment
and are an important consideration when
in the choice of a treatment regimen for
type 2 diabetes. Overall, the rate of hypo-
glycemia in this trial was very low, espe-
cially considering the level of glycemic
control that was achieved. Contrary to
whatmayhavebeenexpected,theinsulin
treatment group had fewer (although not
statistically signiﬁcant) mild and severe
hypoglycemic events than the triple oral
group, illustrating that an insulin-based
regimen can be used to achieve tight gly-
cemic control without fear of excess hy-
poglycemia. Weight gain, although
present in both groups, was less in the
insulin group, indicating that weight
gainisnotacceleratedininsulin-treated
patients compared with a clinically
equivalent oral hypoglycemic treatment
regimen.
Insulin has traditionally been viewed
as a treatment of last resort because of an
undesirable effect on patient QoL and de-
creased treatment satisfaction, leading to
poor compliance. We found that patient
compliance was similar in both groups
(85% compliance with study medica-
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1792 DIABETES CARE, VOLUME 32, NUMBER 10, OCTOBER 2009 care.diabetesjournals.orgFigure 2—Results of modiﬁed Diabetes Quality of Life Questionnaire in the insulin-treated group (f) and triple oral group (E). All patients were
giventhequestionnairetocompleteatrandomizationandat6and18monthsafterrandomization.Patientsrandomlyassignedtooralhypoglycemic
agentsdidnotcompletethetwoquestionsregardinginsulin.TheresultsarereportedasmeansSDoftheLikertscalescoreof1–5.Bothgroupshad
improved scores with respect to social worries and a change toward stable current health perception over time. ANOVA, P  0.005.
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explained by the clinical study environ-
ment, but the similar (or even higher)
compliance with insulin treatment com-
paredwiththeoralagentsisduetotheuse
of a simple insulin regimen with an easy-
to-use insulin-delivery device. In addi-
tion, QoL was not decreased by insulin
treatment, and satisfaction with insulin
was very high. Overall, these ﬁndings re-
fute the myth surrounding poor accep-
tance of insulin treatment by patients,
suggesting that “insulin resistance” lies
mostlyontheproviderside.Thatistosay,
physicians are resistant to the use of
insulin!
Given the progressive decline in
-cell function seen in type 2 diabetes, a
treatment option that has the potential to
preserve -cell function is optimal. There
is mounting evidence that early treatment
with insulin may preserve -cell function
in these patients (10,16,22). In light of
theseﬁndings,inadditiontotheeffective-
ness, safety, and acceptability shown in
our study, we propose that an insulin-
metformin regimen be considered as an
initial treatment option in patients with
newlydiagnosedtype2diabetes.Wecon-
tinue to follow our volunteers to assess
their long-term changes in -cell func-
tion, results that we expect within the
next 2 years.
Commonly cited reasons for avoiding
insulin treatment in type 2 diabetes in-
clude fear of hypoglycemia, weight gain,
and a lack of patient acceptance. Our
study demonstrated that treatment with
insulin and metformin can be used to ob-
tain tight glycemic control in patients
with newly diagnosed type 2 diabetes
without side effects in excess of those
seen with traditional triple oral hypo-
glycemic therapy. This study provides
increasing evidence to persuade physi-
cians that insulin is a viable medical op-
tion for patients with type 2 diabetes
andshouldnotbeviewedasatreatment
of last resort.
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